Disease · MONDO_0031012

autoimmune uveitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. autoimmune uveitis. Diseases, record MONDO_0031012. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0031012

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: autoimmune uveitis; Open Targets
Open Targets ID: MONDO_0031012; Open Targets
Other names: autoimmune uveitis (disease); Open Targets
Disease Ontology: DOID:0040088; Disease Ontology
Highest stage of its drugs: Phase 2, for 1 of its 4 drugs, from ClinicalTrials.gov; Open Targets

Drugs4

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LEFLUNOMIDE	CHEMBL960	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
MINOCYCLINE	CHEMBL1434	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
CURCUMIN	CHEMBL140	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
PHOSPHATIDYLCHOLINE	CHEMBL503481	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	0	Drugs and targets

Targets1

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes
DHODH	Dihydroorotate dehydrogenase (quinone), mitochondrial	1	Dihydroorotate dehydrogenase inhibitor	Phase 2	https://conductscience.org/library/genes/1723

Source Drugs and targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03584724	Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis	Early phase 1	49	2022-03-28	Uveitis	CURCUMIN	Its record names the disease	ClinicalTrials.gov
NCT00001863	Leflunomide to Treat Uveitis	Phase 2	16		Uveitis	LEFLUNOMIDE	Its record names the disease	ClinicalTrials.gov
NCT05474729	Minocycline for Chronic Autoimmune Uveitis	Phase 1/2	10		Minocycline, Uveitis, Retinal Degeneration	MINOCYCLINE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Norflo Oro vs Placebo for Norflo Oro: deaths from any cause	0 of 20	0 of 24	44	NCT03584724	Trial comparisons
Norflo Oro vs Placebo for Norflo Oro: serious adverse events	3 of 20	0 of 24	44	NCT03584724	Trial comparisons

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
35353651	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0031012

GET https://conductscience.org/api/diseases/v1/MONDO_0031012/drugs

API reference For AI assistants